Intuitive Surgical, Inc. $ISRG Stock Acquired by Glenview Trust Co

Glenview Trust Co boosted its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 9.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 138,825 shares of the medical equipment provider’s stock after acquiring an additional 11,896 shares during the quarter. Intuitive Surgical comprises 0.8% of Glenview Trust Co’s holdings, making the stock its 27th largest holding. Glenview Trust Co’s holdings in Intuitive Surgical were worth $56,450,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new stake in shares of Intuitive Surgical during the second quarter worth about $1,335,753,000. Arrowstreet Capital Limited Partnership grew its holdings in Intuitive Surgical by 95.3% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider’s stock worth $970,635,000 after acquiring an additional 1,027,475 shares in the last quarter. Assenagon Asset Management S.A. increased its position in shares of Intuitive Surgical by 55.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,557,940 shares of the medical equipment provider’s stock valued at $633,505,000 after purchasing an additional 558,099 shares during the last quarter. Amundi increased its position in shares of Intuitive Surgical by 8.6% in the 1st quarter. Amundi now owns 2,428,356 shares of the medical equipment provider’s stock valued at $1,119,448,000 after purchasing an additional 193,096 shares during the last quarter. Finally, Temasek Holdings Private Ltd raised its holdings in shares of Intuitive Surgical by 416.4% in the 1st quarter. Temasek Holdings Private Ltd now owns 227,211 shares of the medical equipment provider’s stock valued at $104,742,000 after purchasing an additional 183,211 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Erste Group Bank upgraded shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a research note on Wednesday, October 21st. Stifel Nicolaus cut their price target on Intuitive Surgical from $670.00 to $550.00 and set a “buy” rating on the stock in a research note on Friday, July 17th. Truist Financial decreased their price target on Intuitive Surgical from $580.00 to $510.00 and set a “buy” rating for the company in a report on Thursday, July 16th. Citigroup lowered their price objective on Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating for the company in a research report on Friday, July 17th. Finally, JPMorgan Chase & Co. upped their price objective on Intuitive Surgical from $450.00 to $475.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $493.54.

Intuitive Surgical Price Performance

NASDAQ ISRG opened at $432.01 on Friday. The firm’s fifty day moving average price is $401.54 and its 200 day moving average price is $434.05. Intuitive Surgical, Inc. has a 12 month low of $328.57 and a 12 month high of $603.88. The company has a market capitalization of $149.75 billion, a price-to-earnings ratio of 52.24, a price-to-earnings-growth ratio of 3.09 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.35. Intuitive Surgical had a net margin of 25.54% and a return on equity of 18.17%. The firm had revenue of $3.05 billion during the quarter, compared to analysts’ expectations of $2.91 billion. During the same period in the previous year, the company earned $2.40 earnings per share. Intuitive Surgical’s quarterly revenue was up 21.7% compared to the same quarter last year. As a group, sell-side analysts forecast that Intuitive Surgical, Inc. will post 9.37 earnings per share for the current year.

Insider Buying and Selling at Intuitive Surgical

In other news, Director Gary Guthart sold 20,095 shares of the business’s stock in a transaction dated Friday, October 23rd. The stock was sold at an average price of $451.61, for a total value of $9,075,102.95. Following the completion of the sale, the director directly owned 1,204,530 shares of the company’s stock, valued at approximately $543,977,793.30. The trade was a 1.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Craig Barratt sold 1,150 shares of the company’s stock in a transaction dated Friday, October 23rd. The shares were sold at an average price of $443.80, for a total value of $510,370.00. Following the completion of the sale, the director directly owned 1,150 shares of the company’s stock, valued at approximately $510,370. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 38,778 shares of company stock valued at $16,814,967. 0.60% of the stock is owned by insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.